Rani Therapeutics (RANI) Appoints Lyn Baranowski to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Rani Therapeutics Appoints Lyn Baranowski to Board of Directors
November 12, 2021 4:05 PM ESTSAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Rani Therapeutics or Rani) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Lyn Baranowski to its Board of Directors. Ms. Baranowski is a distinguished biotechnology executive with nearly two decades of experience.
Lyn is a well-respected biotechnology executive whose deep experience includes a diverse set of product portfolios and therapeutic areas, said Talat Imran, Chief Executive Officer of Rani Therapeutics. Lyns track record in creating strategic... More
